Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT5B | Q4FZB7 | 1/20 | 0.53 |
| ▸ | KMT5C | Q86Y97 | 1/20 | 0.53 |
| ▸ | NSD2 | O96028 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 7/20 | 0.49 |
| ▸ | AURKA | O14965 | 5/20 | 0.49 |
| ▸ | MET | P08581 | 5/20 | 0.49 |
| ▸ | TEK | Q02763 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.45 |
| ▸ | LCK | P06239 | 3/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | LYN | P07948 | 1/20 | 0.45 |
| ▸ | FGR | P09769 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6861465 | 1.00 | KMT5B (0.53) | KMT5BKMT5CNSD2KDRAURKA | |
| SCHEMBL6870222 | 0.90 | KMT5B (0.53) | KMT5BKMT5CNSD2KDRAURKA | |
| SCHEMBL6866624 | 0.88 | KMT5B (0.53) | KMT5BKMT5CNSD2KDRAURKA | |
| SCHEMBL6872999 | 0.88 | KMT5B (0.53) | KMT5BKMT5CNSD2KDRAURKA | |
| SCHEMBL6873004 | 0.88 | KMT5B (0.53) | KMT5BKMT5CNSD2KDRAURKA | |
| SCHEMBL6868171 | 0.86 | KMT5B (0.57) | KMT5BKMT5CNSD2KDRAURKA | |
| SCHEMBL6868174 | 0.86 | KMT5B (0.57) | KMT5BKMT5CNSD2KDRAURKA | |
| SCHEMBL6870201 | 0.85 | KMT5B (0.58) | KMT5BKMT5CNSD2KDRKDM4E | |
| SCHEMBL6870204 | 0.85 | KMT5B (0.58) | KMT5BKMT5CNSD2KDRKDM4E | |
| SCHEMBL6865726 | 0.84 | KMT5B (0.57) | KMT5BKMT5CNSD2KDRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818772-B2 | DIETETICS, SLEEP DISORDERS, EATING DISORDERS, SEXUAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS | ABBOTT LABORATORIES | 2004-11-16 | — | — | US | claimed |
| US-20030229119-A1 | Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor | ABBVIE INC. | 2003-12-11 | — | — | US | claimed |
| US-6818772-B2 | DIETETICS, SLEEP DISORDERS, EATING DISORDERS, SEXUAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS | ABBOTT LABORATORIES | 2004-11-16 | — | — | US | disclosed |
| US-20030229119-A1 | Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor | ABBVIE INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003070244-A1 | ANTAGONIST OF MELANIN CONCENTRATING HORMONE AND THEIR USES | ABBOTT LABORATORIES (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229119-A1 | Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor | MCHR1, MCHR2, MC1R | KMT5B 1214/4885KMT5C 1285/4885NSD2 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.